{
    "clinical_study": {
        "@rank": "105899", 
        "acronym": "AHIL", 
        "arm_group": [
            {
                "arm_group_label": "Alcoholic hepatitis", 
                "description": "Patients with alcoholic hepatic; cases."
            }, 
            {
                "arm_group_label": "Healthy controls", 
                "description": "Persons undergoing hepatic resection; controls."
            }
        ], 
        "biospec_descr": {
            "textblock": "Whole blood, serum, plasma, PBMC's, hepatic leukocytes"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the production, effects and interactions of the\n      hepato-protective cytokine interleukine (IL)-22 in patients with alcoholic hepatitis."
        }, 
        "brief_title": "Protective Immune Mechanisms in Alcoholic Hepatitis", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Alcoholic Hepatitis", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Alcoholic"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigators will study hepatic biopsies from patients with alcoholic hepatitis. In\n      these biopsies, the investigators will assess the production of IL-22 and which cells\n      produce the cytokine. The investigators will study the expression of the IL-22 receptor and\n      also the production of the IL-22 binding protein, which can inhibit the actions of the\n      cytokine."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of alcoholic hepatitis:\n\n          -  relevant history of alcohol consumption (>40g/day for a minimum of 6 months with\n             cessation      of consumption no earlier than 3 months prior to admission)\n\n          -  bilirubin > 80 mol/l\n\n          -  neutrophil granulocytes > 10x10^9/L\n\n          -  exclusion of other liver pathology including biliary disease\n\n          -  histological verification on liver biopsy\n\n          -  Written, informed consent\n\n        Exclusion Criteria:\n\n          -  Other chronic inflammatory or autoimmune diseases\n\n          -  Severe, acute bacterial infection (peritonitis, sepsis, pneumonia, urinary tract\n             infection etc.)\n\n          -  Cancer\n\n          -  Prednisolon or pentoxifylline treatment within the past 8 weeks\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "69 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients admitted to the Department of hepatology and gastroenterology V, Aarhus\n        University hospital"
            }
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01918462", 
            "org_study_id": "AHIL", 
            "secondary_id": "AUH"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Alcoholic hepatitis", 
            "IL-22", 
            "Kupffer cells"
        ], 
        "lastchanged_date": "August 5, 2013", 
        "location": {
            "contact": {
                "email": "sidsel.stoy@ki.au.dk", 
                "last_name": "Sidsel St\u00f8y, Phd Student", 
                "phone": "004578464087"
            }, 
            "facility": {
                "address": {
                    "city": "Aarhus", 
                    "country": "Denmark", 
                    "zip": "8000"
                }, 
                "name": "Department of Hepatology and gastroenterology V, Aarhus university hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_groups": "2", 
        "official_title": "Protective Immune Mechanisms in Alcoholic Hepatitis", 
        "overall_contact": {
            "email": "sidsel.stoy@ki.au.dk", 
            "last_name": "Sidsel St\u00f8y", 
            "phone": "004578463897"
        }, 
        "overall_official": {
            "affiliation": "Department of hepatology and gastroenterology, Aarhus University Hospital", 
            "last_name": "Sidsel St\u00f8y, Phd student", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Danish Dataprotection Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This will be detected in hepatic biopsies taken at inclusion to the study.", 
            "measure": "Frequency of IL-22-producing cells", 
            "safety_issue": "No", 
            "time_frame": "at day 1 ( the day of diagnosis/arrival to the department)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01918462"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "This will be detected in hepatic biopsies taken at inclusion to the study.", 
                "measure": "IL-22 binding protein", 
                "safety_issue": "No", 
                "time_frame": "at day 1 ( the day of diagnosis/arrival to the department)"
            }, 
            {
                "description": "This will be detected in hepatic biopsies taken at inclusion to the study.", 
                "measure": "IL-22 receptor", 
                "safety_issue": "No", 
                "time_frame": "at day 1 ( the day of diagnosis/arrival to the department)"
            }, 
            {
                "description": "Thse measurements will be done on blood samples drawn at inclusion, at day 7 and at day 30.", 
                "measure": "Signalling molecules and markers of hepatocyte destruction", 
                "safety_issue": "No", 
                "time_frame": "at day 1, at day 7 and at day 30 after diagnosis."
            }
        ], 
        "source": "University of Aarhus", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Aarhus", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2013"
    }
}